• Sean Lee from H.C. Wainwright set a new price target of $27 for NASDAQ:CRVS, indicating a potential increase of approximately 48.19%.
• The stock price of Corvus Pharmaceuticals reached an eight-year high following the release of promising eczema treatment results.
• With a market capitalization of approximately $1.36 billion and a trading volume of 54.94 million shares, Corvus Pharmaceuticals demonstrates strong investor interest and confidence.

Corvus Pharmaceuticals (NASDAQ:CRVS) is a small biotech company focused on developing innovative treatments for various medical conditions. Recently, the company has gained significant attention due to its promising advancements in eczema treatment. This has led to a notable increase in its stock price, reflecting the market's positive reception of its progress.

On January 20, 2026, Sean Lee from H.C. Wainwright set a new price target of $27 for CRVS. At the time, the stock was trading at $18.22, suggesting a potential increase of approximately 48.19%. This optimistic outlook aligns with the recent surge in the stock price, which reached an eight-year high following the release of promising eczema treatment results.

The stock for CRVS is currently priced at $18.20, marking a significant increase of 126.09% with a change of $10.15. This price movement underscores the market's confidence in Corvus Pharmaceuticals' potential impact in the biotech sector. The stock has fluctuated between a low of $12.69 and a high of $19.12 today, with $19.12 being its highest price for the year.

Corvus Pharmaceuticals has a market capitalization of approximately $1.36 billion, reflecting its growing presence in the biotech industry. The trading volume for the day is 54.94 million shares, indicating strong investor interest. As the company continues to develop innovative treatments, it remains a key player to watch in the biotech sector.